Codeine, one of the world’s most widely used opioids, plays a significant role in modern medicine despite growing concerns about its potential for misuse. This comprehensive review explores the pharmacological properties, clinical applications, and safety considerations of this important medication.
Introduction
Codeine is a naturally occurring alkaloid found in the opium poppy plant (Papaver somniferum) and belongs to the opioid class of medications. It is classified as a natural opioid and is included on the World Health Organization’s list of essential medicines for adults, though it was removed from the children’s list in 2011. As the most commonly taken opioid medication globally, codeine is widely used for treating mild to moderate pain, suppressing cough, and managing diarrhea.
Despite its therapeutic benefits, codeine possesses significant potential for dependence, with approximately 2% of admissions to substance abuse centers attributed to codeine dependence. In recreational settings, codeine is known by various street names including “little c,” “Cody,” “Captain Cody,” “lean,” and “Schoolboy,” while codeine syrup mixed with soft drinks is referred to as “Texas tea,” “sizzurp,” or “purple drank”.
Chemical Structure
Codeine, chemically known as 3-methylmorphine, has the molecular formula C₁₈H₂₁NO₃ and a molecular weight of 299.37 g/mol. Its structure closely resembles that of morphine, with the primary difference being a methyl group substituted for the hydroxyl group on the number 3 carbon of the morphine molecule. The IUPAC name is (5α,6α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol.
Codeine contains several stereocenters, making its three-dimensional structure critical to its biological activity. This slight structural modification from morphine significantly impacts its pharmacological properties, including absorption, metabolism, and potency.
Codeine-Based Medicines List
Codeine is available in numerous pharmaceutical formulations, both as a single agent and in combination with other medications. Here are the top eight codeine-containing products:
- Tylenol #3 and #4 – Codeine combined with acetaminophen for pain management
- Codeine Contin – Extended-release codeine formulation for sustained pain relief
- Tuzistra XR – Codeine containing chlorpheniramine for cough and cold symptoms
- Fioricet with Codeine – Combination product for tension headaches containing codeine, acetaminophen, butalbital, and caffeine
- Ascomp – Codeine combination product for pain relief
- Cheratussin – Codeine-containing cough formulation
- Mersyndol – Combination product containing codeine, paracetamol, and antihistamine
- Triacin-C – Codeine formulation for cough suppression
These medications are available in various forms including tablets, syrups, and extended-release formulations, depending on the specific product and regional regulations.
Mechanism of Action
Codeine functions primarily as a prodrug, requiring metabolic conversion to exert its therapeutic effects. Its mechanism involves several key processes:
Codeine itself is metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme system in the liver, converting approximately 5-10% of the codeine to morphine, which is primarily responsible for the analgesic effects. As a weak opioid, codeine binds to the three classic opioid receptors (mu, delta, and kappa), though it demonstrates 20 times more affinity for the mu receptor compared to delta receptors and significantly less selectivity for kappa receptors.
Once converted to morphine, it binds predominantly to mu-opioid receptors in the brain and spinal cord, triggering intracellular events that result in decreased cAMP, hyperpolarization of neuronal cells, and inhibition of nociceptive neurotransmitter release.
This modulates pain perception and transmission throughout the central nervous system. The cough suppression (antitussive) effects occur primarily through activation of opioid receptors in the medulla, the part of the brain responsible for regulating the cough reflex. This multi-pathway mechanism allows codeine to address both pain and cough through related but distinct neurological actions.
Pharmacokinetics
The pharmacokinetic profile of codeine involves several distinct phases that determine its efficacy and duration of action:
Absorption: Codeine demonstrates excellent bioavailability, with approximately 94% absorption from the gastrointestinal tract following oral administration. Peak plasma concentrations (Cmax) are typically achieved within one hour after ingestion. When administered every four hours, steady-state concentrations are reached after approximately 48 hours. Most food types do not significantly affect codeine absorption, making timing relative to meals less critical than with some other medications.
Distribution: Codeine exhibits an apparent volume of distribution between 3 and 6 L/kg, indicating extensive tissue distribution throughout the body. This wide distribution contributes to its systemic effects on multiple organ systems.
Metabolism: The metabolism of codeine follows first-order kinetics, meaning its rate of metabolism is proportional to plasma concentration. The primary pathways include conversion to morphine (5-10%) via CYP2D6, N-demethylation to norcodeine (approximately 10%) via CYP3A4, and glucuronidation through UGT2B7 to form various metabolites. Significant interindividual variability in metabolism exists due to genetic polymorphisms in CYP2D6, creating distinct metabolizer phenotypes ranging from poor to ultra-rapid.
Excretion: Approximately 90% of codeine is excreted through the kidneys, with about 10% eliminated unchanged in urine. The elimination half-life of codeine and its metabolites averages about 3 hours in healthy individuals but can be significantly prolonged in patients with renal impairment, potentially extending to 18.69 hours in end-stage renal disease patients compared to 4.04 hours in healthy volunteers.
Therapeutic Uses
Codeine has several approved and established therapeutic applications in clinical practice:
| Therapeutic Use | Description | Common Dosage Forms | Target Population |
|---|---|---|---|
| Pain Management | Treatment of mild to moderate pain, often combined with acetaminophen or NSAIDs for enhanced effect | Tablets, oral solution | Adults and adolescents over 12 |
| Cough Suppression | Management of persistent dry cough, particularly in respiratory infections | Syrups, linctus | Adults (restricted in children under 12) |
| Diarrhea Control | Treatment of persistent diarrhea when other interventions have failed | Tablets, oral solution | Adults |
| Palliative Care | Management of various symptoms in end-of-life and serious illness contexts | Multiple formulations | Adult patients in palliative care |
Side Effects
Codeine can produce a wide spectrum of adverse effects ranging from common and mild to rare but potentially serious:
The most common side effects include gastrointestinal disturbances such as nausea, vomiting, stomach pain, and constipation, which affect a significant proportion of users. Central nervous system effects are also frequently reported, including drowsiness, dizziness, lightheadedness, and headache. Many patients also experience difficulty urinating and itchiness, particularly with regular or higher-dose use.
More serious adverse effects require immediate medical attention and include respiratory depression, manifesting as noisy or shallow breathing or difficulty breathing, which can be life-threatening, especially during the first 24 to 72 hours of treatment. Neurological complications such as seizures, hallucinations, confusion, and agitation may occur, particularly with higher doses or in susceptible individuals.
Cardiovascular effects including irregular heartbeat have been reported, while allergic reactions may manifest as rash, hives, itching, or swelling of the face, lips, tongue, or throat. Some patients may develop adrenal gland problems, indicated by symptoms such as darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, and weakness.
Drug Interactions
Codeine participates in numerous clinically significant drug interactions that can alter its efficacy and safety profile:
Medications that inhibit CYP2D6 enzyme activity, such as bupropion, fluoxetine, paroxetine, and quinidine, can significantly decrease the conversion of codeine to morphine, potentially reducing its analgesic effects. Conversely, CYP3A4 inhibitors including macrolide antibiotics, protease inhibitors, and azole antifungal agents may increase morphine availability from codeine metabolism, potentially enhancing both therapeutic effects and side effects.
Patients taking CYP3A4 inducers such as carbamazepine, phenytoin, and rifampicin may experience increased norcodeine levels and decreased morphine levels, potentially reducing analgesic efficacy. Dietary components can also affect codeine metabolism, with grapefruit juice and grapefruit potentially altering metabolism through effects on CYP enzymes. These complex interactions highlight the importance of comprehensive medication review before initiating codeine therapy.
Safety Considerations
Several important safety concerns must be considered when prescribing or using codeine:
Genetic variability in codeine metabolism creates significant safety concerns, with approximately 3% of African-Americans, 1-10% of White individuals, and 11-30% of North Africans classified as ultra-rapid metabolizers who convert codeine to morphine more quickly, potentially resulting in toxicity even at standard doses.
Children are particularly vulnerable to codeine’s adverse effects, leading to contraindications for use in those under 12 years of age for cough and cold symptoms and caution in those aged 12-18 with respiratory problems.
Codeine is contraindicated in known ultra-rapid metabolizers of any age and in breastfeeding mothers, as the drug can pass into breast milk and potentially harm nursing infant. The risk of opioid dependence and addiction is substantial, requiring careful patient selection, monitoring, and appropriate prescribing practices. Particular caution is warranted in patients with compromised respiratory function, as codeine can further suppress respiration, and in those with renal impairment, as elimination half-life can be significantly prolonged. These safety considerations necessitate a personalized risk assessment before initiating codeine therapy.
Regulatory Status
Codeine’s regulatory classification varies globally, reflecting evolving understanding of its risk-benefit profile:
In the United States, codeine’s regulatory status depends on its formulation. As a combination product, codeine falls into Schedule III-V of the Controlled Substance Schedule, while in pure form, it is classified as a Schedule II opioid, reflecting its higher abuse potentia.
An international regulatory shift is occurring regarding codeine’s accessibility, with countries like the UK recently reclassifying codeine linctus from over-the-counter to prescription-only status due to concerns about abuse and addiction.
Accessibility varies significantly by country-codeine remains available as an over-the-counter medication in Denmark, Japan, Poland, and historically in parts of the UK, while requiring prescriptions in countries including the USA and Australia.
The European Medicines Agency has implemented restrictions on codeine use in pediatric populations, contraindicating it for cough and cold in children under 12 and recommending against its use in children and adolescents aged 12-18 with breathing problems. These evolving regulations reflect increasing concerns about codeine misuse, with particular attention to its recreational use in preparations known as “Purple Drank” or “Lean”.
Conclusion
Codeine represents a complex pharmacological agent with substantial therapeutic utility but significant safety concerns. Its effectiveness in managing pain, cough, and diarrhea must be balanced against its potential for adverse effects, drug interactions, and misuse.
The variability in individual metabolism of codeine, particularly through the CYP2D6 pathway, creates unique challenges for prescribers in predicting response and avoiding toxicity. Recent regulatory changes reflect growing concerns about codeine’s risk profile, especially in vulnerable populations such as children and those with genetic predispositions to rapid metabolism.
As medical understanding continues to evolve, the appropriate use of codeine requires careful patient selection, thorough medication review, and ongoing monitoring. Healthcare providers must remain vigilant about changing regulations and emerging safety data to optimize therapeutic outcomes while minimizing risks. For patients, awareness of potential side effects and adherence to prescribed dosing regimens remain essential components of safe codeine use. Through balanced consideration of both benefits and risks, codeine can maintain its important role in the therapeutic armamentarium while minimizing potential harms.
